Literature DB >> 27345784

Generation of integration free induced pluripotent stem cells from fibrodysplasia ossificans progressiva (FOP) patients from urine samples.

Laura Hildebrand1, Bella Rossbach1, Peter Kühnen2, Manfred Gossen3, Andreas Kurtz4, Petra Reinke1, Petra Seemann1, Harald Stachelscheid5.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is an extremely rare, autosomal dominant transmitted genetic disease. Patients experience progressive bone formation replacing tendons, ligaments, muscle and soft tissue. Cause of FOP are gain-of-function mutations in the Bone Morphogenetic Protein (BMP) receptor Activin A receptor type 1 (ACVR1) (Kaplan et al., 2008). The most common mutation is R206H, which leads to the substitution of codon 206 from arginine to histidine (Shore et al., 2006). Here, we describe the derivation and characterization of two hiPSC lines from two FOP patients, both carrying the mutation R206H. Cells were isolated from urine and reprogrammed using integration free Sendai virus vectors under defined conditions.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27345784     DOI: 10.1016/j.scr.2015.11.017

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  10 in total

Review 1.  Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.

Authors:  Emilie Barruet; Edward C Hsiao
Journal:  Bone       Date:  2017-07-14       Impact factor: 4.398

Review 2.  Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Authors:  Zijuan Qi; Jing Luan; Xiaoyan Zhou; Yazhou Cui; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 3.  Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases.

Authors:  Liang Shi; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2016-08

4.  ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.

Authors:  Susanne Hildebrandt; Branka Kampfrath; Kristin Fischer; Laura Hildebrand; Julia Haupt; Harald Stachelscheid; Petra Knaus
Journal:  Stem Cell Rev Rep       Date:  2021-01-07       Impact factor: 5.739

5.  Inflammatory Responses and Barrier Function of Endothelial Cells Derived from Human Induced Pluripotent Stem Cells.

Authors:  Oleh V Halaidych; Christian Freund; Francijna van den Hil; Daniela C F Salvatori; Mara Riminucci; Christine L Mummery; Valeria V Orlova
Journal:  Stem Cell Reports       Date:  2018-04-12       Impact factor: 7.765

Review 6.  Urine-Derived Stem Cells: The Present and the Future.

Authors:  Xiaoli Ji; Min Wang; Fang Chen; Junmei Zhou
Journal:  Stem Cells Int       Date:  2017-11-08       Impact factor: 5.443

Review 7.  Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review).

Authors:  Fuli Shi; Jiayu Gao; Junrong Zou; Ying Ying; Hui Lin
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

Review 8.  Urine-Derived Stem Cells: Applications in Regenerative and Predictive Medicine.

Authors:  Guida Bento; Aygul K Shafigullina; Albert A Rizvanov; Vilma A Sardão; Maria Paula Macedo; Paulo J Oliveira
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

Review 9.  An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells.

Authors:  Arnab Ray; Jahnavy Madhukar Joshi; Pradeep Kumar Sundaravadivelu; Khyati Raina; Nibedita Lenka; Vishwas Kaveeshwar; Rajkumar P Thummer
Journal:  Stem Cell Rev Rep       Date:  2021-06-07       Impact factor: 5.739

10.  Generation of gene-corrected functional osteoclasts from osteopetrotic induced pluripotent stem cells.

Authors:  Xiaojie Xian; Roksana Moraghebi; Henrik Löfvall; Anders Fasth; Kim Henriksen; Johan Richter; Niels-Bjarne Woods; Ilana Moscatelli
Journal:  Stem Cell Res Ther       Date:  2020-05-15       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.